For individuals battling Transthyretin Amyloid Cardiomyopathy (ATTR-CM), a serious condition, the introduction of this treatment and Attruby represents a true change. These novel therapies protect the transthyretin protein, halting its harmful build-up and lessening the impact of the condition .